AAV vectors for in vivo gene therapy of rheumatoid arthritis
US8529885B2 · kind B2 · utility
3Cited by
4References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 1, 2004 |
| Grant date | Sep 10, 2013 |
| Priority date | — |
| Expiry date | Sep 1, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P19/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the field of adeno-associated virus (AAV) based gene therapy, in particular in vivo gene therapy, of rheumatoid arthritis (RA). The invention provides recombinant AAV virions being highly efficient in delivering genes encoding therapeutic proteins to the arthritic joints, and method for using such virions in in vivo gene therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.